secwatch.observer — SEC 8-K summary
======================================

Issuer:     Edesa Biotech, Inc. (EDSA)
CIK:        0001540159
Form:       8-K
Filed at:   2024-05-10T23:59:59+00:00
Accession:  0001654954-24-005965
Event type: earnings
Sentiment:  neutral
Materiality: 0.55
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Edesa Biotech Q2 FY2024 net loss $1.9M ($0.58/shr); advances ARDS Phase 3 and vitiligo study
--------------------------------------------------------------------------------

- Net loss narrowed to $1.9M vs $2.3M YoY; six-month loss $3.5M ($1.12/shr).
- Cash $2.8M at March 31; received $0.7M post-quarter from Canadian govt funding.
- Expanding Phase 3 ARDS trial with EB05; up to C$23M govt support secured.
- Plans to file IND for Phase 2 pulmonary fibrosis study with EB05.
- Seeks U.S. approval for Phase 2 vitiligo study; pursuing strategic deals for EB01.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1540159/000165495424005965/0001654954-24-005965-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1540159/000165495424005965/edsa_8k.htm
  HTML page:      https://secwatch.observer/filing/0001654954-24-005965

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer